ReviewFrontiers in bioengineering and biotechnology2025
Mechanism and application of injectable hydrogel as carrier system in the treatment of osteoarthritis.
Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- [Research progress on immune microenvironment imbalance and targeted interventions in osteoarthritis comorbid with diabetes mellitus].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026Review
- Development of an injectable thermosensitive hydrogel depot system for controlled and sustained subcutaneous drug delivery.International journal of pharmaceutics: X · 2026Article
- Hydrogel-Based Therapeutic Strategies for Post-Cholecystectomy NAFLD: Targeting Bile Acid Signaling, Gut Microbiota, Inflammation, and Hepatic Fibrosis.Gels (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a disabling degenerative disease that affects synovial joints and leads to cartilage degeneration, which can cause progressive joint damage, chronic pain and functional loss. Because its specific pathogenesis is still unclear, conventional treatment methods are still difficult to achieve satisfactory therapeutic effects. Therefore, finding alternative new methods for treating OA remains a formidable challenge. Hydrogel is a kind of polymer material with good biocompatibility and biodegradability, and it is a new method for the treatment of osteoarthritis. Injectable hydrogel drug delivery platforms have shown many advantages in the treatment of OA, including improved biocompatibility, biodegradability, and low immunogenicity. Injectable hydrogels, as delivery systems, can deliver drugs to the joint cavity in a controlled manner and continuously release them, enhancing drug loading capacity and increasing sensitivity to improve therapeutic effects. This article summarizes the types of injectable hydrogels, analyzes their application as delivery systems in OA, and discusses the mechanisms of injectable hydrogels in the treatment of OA, such as anti-inflammation, anti-oxidative stress, and promotion of articular cartilage regeneration. Meanwhile, the deficiencies of injectable hydrogel drug delivery platforms in the OA field were summarized, and the future research directions in this field were discussed. Overall, injectable hydrogel drug delivery platforms show great potential in the treatment of OA. These innovative methods have brought new hope for the future treatment of OA and pointed out the direction for clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.